{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:07:24Z","timestamp":1777766844860,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T00:00:00Z","timestamp":1252454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T00:00:00Z","timestamp":1252454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"abstract":"<jats:p>Fourteen patients with chronic genital warts were entered in a pair-matched crossover trial of recombinant interferon-\u03b1-2a. They received daily doses of either 1.5 \u00d7 106 U or 18 \u00d7 106 U interferon for one week by the subcutaneous route (abdominal skin). After an observation period of 4 weeks in case of no change or partial response, patients of the low-dose group were given 18 \u00d7 106 U and those of the high-dose group 3 \u00d7 106 U daily for another 7 days. Eight of 14 patients had a complete remission by the end of the therapy-free interval of 4 weeks, 5 patients of the low-dose group and 3 patients of the high-dose group. Acute side-effects consisted of a transient influenza-like syndrome. Remissions have been maintained for 6 to over 10 months. The data implicate that recombinant interferon-\u03b1-2a is highly effective in patients with human papillomavirus-related genital warts and that the low-dose regimen is at least equivalent to the high-dose treatment.<\/jats:p>","DOI":"10.1159\/000238464","type":"journal-article","created":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T09:21:59Z","timestamp":1252488119000},"page":"537-541","source":"Crossref","is-referenced-by-count":56,"title":["Systemic Treatment of Condylomata Acuminata with Recombinant Interferon-Alpha-2A: Low-Dose Superior to the High-Dose Regimen"],"prefix":"10.1159","author":[{"given":"G.","family":"Gross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Ikenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Roussaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Drees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Sch\u00f6pf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,9,9]]},"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/238464","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000238464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:36:59Z","timestamp":1777477019000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000238464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,9]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000238464","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,9]]}}}